Literature DB >> 7114041

Nonestrogenic drugs and breast cancer.

D A Danielson, H Jick, J R Hunter, A Stergachis, S Madsen.   

Abstract

The relation between breast cancer and selected nonestrogenic drugs was evaluated in the Group Health Cooperative of Puget Sound, Seattle, Washington, a prepaid health care organization with computerized information on diagnoses and outpatient drug use. No important positive associations with breast cancer were found in a follow-up study of 302 women aged 35-74 years. These women were newly diagnosed with breast cancer in 1977-1980 and were studied in relation to exposure in the six months prior to diagnosis to one or more of the following drugs: diazepam, digitalis glycosides, medroxyprogesterone acetate, methyldopa, metronidazole, phenothiazines, tricyclic antidepressants, thiazides, thyroid/levothyroxine sodium, or spironolactone. A modest association between recent reserpine use and breast cancer was present (risk ratio = 1.7, 90% confidence interval 0.9-3.3).

Entities:  

Mesh:

Year:  1982        PMID: 7114041     DOI: 10.1093/oxfordjournals.aje.a113416

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  15 in total

Review 1.  Depot medroxyprogesterone acetate and breast cancer. A review of current knowledge.

Authors:  C E Chilvers
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

Review 2.  Digitalis Use and the Risk of Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Chen Zhang; Shao-Hua Xie; Bingfei Xu; Shi Lu; Pian Liu
Journal:  Drug Saf       Date:  2017-04       Impact factor: 5.606

3.  [Spironolactone in dermatological treatment. On and off label indications].

Authors:  C M Salavastru; K Fritz; G S Tiplica
Journal:  Hautarzt       Date:  2013-10       Impact factor: 0.751

4.  Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience.

Authors:  Grace K Kim; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2012-03

Review 5.  Does thyroid dysfunction increase the risk of breast cancer? A systematic review and meta-analysis.

Authors:  Y Fang; L Yao; J Sun; R Yang; Y Chen; J Tian; K Yang; L Tian
Journal:  J Endocrinol Invest       Date:  2017-05-17       Impact factor: 4.256

Review 6.  Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry.

Authors:  Lisa Cosgrove; Ling Shi; David E Creasey; Maria Anaya-McKivergan; Jessica A Myers; Krista F Huybrechts
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

7.  Breast cancer recurrence risk in relation to antidepressant use after diagnosis.

Authors:  Jessica Chubak; Diana S M Buist; Denise M Boudreau; Mary Anne Rossing; Thomas Lumley; Noel S Weiss
Journal:  Breast Cancer Res Treat       Date:  2007-12-06       Impact factor: 4.872

Review 8.  Nonhormonal drugs and cancer.

Authors:  P D Stolley; S H Zahm
Journal:  Environ Health Perspect       Date:  1995-11       Impact factor: 9.031

9.  The effects of tricyclic antidepressants on breast cancer risk.

Authors:  C R Sharpe; J-P Collet; E Belzile; J A Hanley; J-F Boivin
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

10.  Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.

Authors:  Isla S Mackenzie; Thomas M Macdonald; Alastair Thompson; Steve Morant; Li Wei
Journal:  BMJ       Date:  2012-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.